Biotechnology
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-...
2022-06-06 13:15
2401
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-...
2022-06-06 12:23
1983
GILEAD SCIENCES APPOINTS DUSTIN HAINES AS NEW LEADER FOR ASIA 5 REGION
-- Mr Haines Brings a Strong Track Record of Global Commercial Successes and Corporate Leadership with a Career that Spans 20 Years in Pharmaceuticals -- -- He Joins Gilead's Asia 5 Team as the Company Celebrates 10 Years of Presence inAsia -- HONG KONG, June 6, 2022 /PRNewswire/ -- Gilead Scien...
2022-06-06 11:00
3503
OriCiro Announces Series B2 Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic Biology
TOKYO, June 5, 2022 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, today announced that it has closed Series B2 financing from Asahi Kasei Medical Co., Ltd. OriCiro has advanced its busine...
2022-06-06 10:09
1605
Research Updates on KN046 Presented at 2022 ASCO
SUZHOU, China, June 6, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that research updates from four clinical studies of KN046 (PD-L1/CTLA-4 bispecific antibody) presented as a poster or published online at the 2022 American Society of Clinical Oncology Annual Meeting (20...
2022-06-06 09:47
2494
WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes
* WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-filled syringes (PFS) capacity to 17 million units per year. * WuXi Biologics has established a global manufacturing network with 9 drug p...
2022-06-06 08:30
3252
JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting
SHANGHAI, June 5, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the latest data of three clinical studies on Carteyva® (relmacabtagene autoleuce...
2022-06-05 18:30
3684
Gracell Biotechnologies Schedules Clinical Update Call After EHA2022
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, June. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today a...
2022-06-03 23:00
6169
KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE
SYDNEY, June 3, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The data is the subj...
2022-06-03 19:00
8456
Sanyou Super-Trillion Innovative Antibody Drug Discovery Platform Announced - World Premiere
SHANGHAI, June 2, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals officially
launched STAL (Super-Trillion Antibody Libraries) onJune 3, 2022, which is a
super-trillion innovative antibody drug discovery platform of Sanyou's own
intellectual property.
2022-06-03 08:00
2249
IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
SHANGHAI, NANJING, China, and SAN JOSE , Calif., June 2, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innoven...
2022-06-02 20:08
2995
ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic
- Advance PRO1184 and PRO1160 into clinical trials - Accelerate multiple programs into preclinical development and further strengthen/expand innovative technology platforms - Build vertically integrated internal capabilities for more efficient drug development WOODINVILLE, Wash. and SUZHOU, China...
2022-06-02 20:00
2312
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profound disability MELBOURNE, Australia, June 2, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disea...
2022-06-02 20:00
2240
Vazyme Releases 2021 Annual Report: Announces More Efforts in Technology innovation and Together with Partners for a Better Future
NANJING, China, June 2, 2022 /PRNewswire/ -- Vazyme, China's leading biotechnology company, has recently released its 2021 annual report, revealing that the company has maintained a steady and solid growth throughout the past year. The report shows that it has achieved$289 million in operating in...
2022-06-02 12:54
2828
Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022
SUZHOU, China, June 2, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that clinical data for...
2022-06-02 08:08
2504
Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares
SUZHOU, China, June 2, 2022 /PRNewswire/ -- On June 1, 2022, TOT BIOPHARM International Company Limited (TOT BIOPHARM, Stock code: 1875.HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and C...
2022-06-02 08:00
5586
Standigm Signs MOU with Merck Korea for AI drug Discovery Research
- Merck's retrosynthesis AI software SYNTHIA™ accelerates Standigm's synthesis capability SEOUL, South Korea, June 1, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Und...
2022-06-01 21:00
2135
Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit
SHANGHAI, June 1, 2022 /PRNewswire/ -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock") announced that it has received CE marking for its OverC™ Multi-Cancer Detection Blood Test manufactured in both the US and China facilities (Identification Number: DE/CA20/01-IVD-Luxu...
2022-06-01 19:49
1571
AMGEN AND NSG BIOLABS ANNOUNCE GOLDEN TICKET TO BOOST SINGAPORE'S BIOTECH ECOSYSTEM
Amgen is the inaugural sponsor of the NSG Tomorrow Programme that aims to
support innovation among biotech startups inSoutheast Asia
SINGAPORE, June 1, 2022 /PRNewswire/ -- Amgen
2022-06-01 10:00
2724
Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting
Poster will report data from the Phase I/II TORCH-2 Study that evaluates ATG-008 (onataseritb) and toripalimab in patients with advanced solid tumors TORCH-2 is the world's first clinical study evaluating the combination of a dual mTORC1/2 inhibitor and an anti-PD-1 monoclonal antibody SHANGHAI ...
2022-06-01 08:30
2247
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 292 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 290 media titles]
2024-04-22 06:00
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 287 media titles]
2024-04-18 21:26
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 286 media titles]
2024-04-19 13:25
Animated Life in Yunnan
[Picked up by 281 media titles]
2024-04-18 14:00
Most Read
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
2024-04-18 21:26
8827
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
8517
Animated Life in Yunnan
2024-04-18 14:00
7810
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
2024-04-19 13:25
7314
IQAX eBL Wins Prestigious APTFF Trade Facilitation Innovation Award 2024
2024-04-18 10:36
3888